Methotrexate
Treatment for Crohns Disease
Typical Dosage: 15-25 mg weekly, oral or subcutaneous
Effectiveness
55%
Safety Score
30%
Clinical Trials
24
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
15-25 mg weekly, oral or subcutaneous
Time to Effect
8-12 weeks
Treatment Duration
long-term
Evidence Quality
MODERATENumber Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$850
Side Effect Mgmt:$200
Total Annual:$1,250
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$10,000/QALY
QALYs Gained
0.03
Outcome-Based Costs
Cost per Responder
$2,778
Cost per Remission
$5,000
Active Clinical Trials
5 active trials recruiting for Methotrexate in Crohns Disease
InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease
NCT06059989RECRUITINGPHASE3
158 participants
INTERVENTIONAL
Amsterdam, Netherlands
Started: Nov 25, 2021
Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease
NCT06673134ACTIVE NOT RECRUITING
100 participants
OBSERVATIONAL
Wuhan, China
Started: Dec 1, 2023
Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial
NCT05040464RECRUITINGPHASE3
166 participants
INTERVENTIONAL
Amiens, France
Started: Aug 26, 2021
Ibd CAncer and seRious Infections in France (I-CARE 2)
NCT06089590RECRUITING
6K participants
OBSERVATIONAL
Amiens, France +1 more
Started: Jan 25, 2024
Combined Immunosuppression for Pediatric Crohn's Disease
NCT05043870RECRUITINGPHASE4
128 participants
INTERVENTIONAL
Shanghai, China
Started: Oct 10, 2022
Completed Clinical Trials
10 completed trials for Methotrexate in Crohns Disease
Salvage Therapy With High/Low Methotrexate for Loss of Response to Infliximab Dose Escalation
NCT02269358COMPLETEDPHASE4
22 participants
INTERVENTIONAL
Holon, Israel
Started: Jul 1, 2015
COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial)
NCT00132899COMPLETEDPHASE3
128 participants
INTERVENTIONAL
London, Canada
Started: Dec 1, 2005
Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
NCT02772965COMPLETEDPHASE3
306 participants
INTERVENTIONAL
Birmingham, United States +31 more
Started: Oct 1, 2016
Triple Combination Therapy in High Risk Crohn's Disease (CD)
NCT02764762COMPLETEDPHASE4
55 participants
INTERVENTIONAL
Dothan, United States +31 more
Started: Apr 18, 2017
Early Immunosuppressants in Crohn's Disease
NCT00546546COMPLETEDPHASE4
120 participants
INTERVENTIONAL
Amiens, France +25 more
Started: Jul 1, 2005
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
NCT02177071COMPLETEDPHASE4
211 participants
INTERVENTIONAL
Melbourne, Australia +26 more
Started: Oct 9, 2015
Reduce Risk for Crohn's Disease Patients
NCT02852694COMPLETEDPHASE4
192 participants
INTERVENTIONAL
Paris, France
Started: Feb 28, 2017
Top Down Versus Step Up Strategies in Crohn's Disease
NCT00554710COMPLETEDPHASE4
129 participants
INTERVENTIONAL
Bonheiden, Belgium
Started: May 1, 2001
Study Evaluating the Persistence, Efficacy and Tolerability of Methotrexate in Inflammatory Bowel Disease Patients
NCT05927064COMPLETED
1.28K participants
OBSERVATIONAL
Vandœuvre-lès-Nancy, France
Started: Jul 21, 2023
Switching From Intravenous to Subcutaneous Infliximab in Adult Patients With Inflammatory Bowel Disease
NCT06381518COMPLETEDNA
38 participants
INTERVENTIONAL
Sittard, Netherlands
Started: Mar 12, 2024
Showing 20 of 24 total trials